Go Pro
NASDAQ:IBIO

iBio Q1 2025 Earnings Report

iBio logo
$1.12 +0.02 (+1.35%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$1.10 -0.02 (-2.22%)
As of 10/2/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

iBio EPS Results

Actual EPS
-$0.46
Consensus EPS
-$0.46
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

iBio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

iBio Announcement Details

Quarter
Q1 2025
Time
After Market Closes
Conference Call Date
Tuesday, November 12, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

iBio's Q1 2027 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

iBio Earnings Headlines

iBio (NASDAQ:IBIO) and Organogenesis (NASDAQ:ORGO) Head to Head Review
iBio, Inc. (NASDAQ:IBIO) Stock Has Consensus Price Target of $5.29
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.tc pixel
See More iBio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like iBio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on iBio and other key companies, straight to your email.

About iBio

iBio (NASDAQ:IBIO) is a biotechnology company focused on discovering and developing next-generation antibody therapeutics. The company uses artificial intelligence, machine learning and computational biology to identify antibody candidates and optimize their properties for potential use in cancer, autoimmune, inflammatory and fibrotic diseases.

iBio’s technology platform is based in part on the antibody-discovery capabilities obtained through its acquisition of RubrYc Therapeutics. The platform is designed to support target selection, antibody generation and optimization, with an emphasis on identifying antibodies that bind specific disease-related epitopes. iBio is advancing its own discovery programs while also pursuing collaborations and licensing opportunities with pharmaceutical and biotechnology companies.

Historically, iBio operated as a biologics manufacturing and development company and was known for its FastPharming plant-based protein-production technology. The company has since shifted its primary focus toward artificial intelligence-enabled antibody discovery and therapeutic development. iBio is led by President and Chief Executive Officer Martin Brenner, Ph.D.

View iBio Profile